152 related articles for article (PubMed ID: 33274278)
1. Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists.
Jacobson ME; Becker KW; Palmer CR; Pastora LE; Fletcher RB; Collins KA; Fedorova O; Duvall CL; Pyle AM; Wilson JT
ACS Cent Sci; 2020 Nov; 6(11):2008-2022. PubMed ID: 33274278
[TBL] [Abstract][Full Text] [Related]
2. Covalent Polymer-RNA Conjugates for Potent Activation of the RIG-I Pathway.
Palmer CR; Pastora LE; Kimmel BR; Pagendarm HM; Kwiatkowski AJ; Stone PT; Arora K; Francini N; Fedorova O; Pyle AM; Wilson JT
Adv Healthc Mater; 2024 Apr; ():e2303815. PubMed ID: 38648653
[TBL] [Abstract][Full Text] [Related]
3. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
5. 'Smart' delivery systems for biomolecular therapeutics.
Stayton PS; El-Sayed ME; Murthy N; Bulmus V; Lackey C; Cheung C; Hoffman AS
Orthod Craniofac Res; 2005 Aug; 8(3):219-25. PubMed ID: 16022724
[TBL] [Abstract][Full Text] [Related]
6. Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs.
Palmer CR; Jacobson ME; Fedorova O; Pyle AM; Wilson JT
Bioconjug Chem; 2018 Mar; 29(3):742-747. PubMed ID: 29350913
[TBL] [Abstract][Full Text] [Related]
7. RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection.
Coch C; Stümpel JP; Lilien-Waldau V; Wohlleber D; Kümmerer BM; Bekeredjian-Ding I; Kochs G; Garbi N; Herberhold S; Schuberth-Wagner C; Ludwig J; Barchet W; Schlee M; Hoerauf A; Bootz F; Staeheli P; Hartmann G; Hartmann E
Mol Ther; 2017 Sep; 25(9):2093-2103. PubMed ID: 28760668
[TBL] [Abstract][Full Text] [Related]
8. RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.
Engel C; Brügmann G; Lambing S; Mühlenbeck LH; Marx S; Hagen C; Horváth D; Goldeck M; Ludwig J; Herzner AM; Drijfhout JW; Wenzel D; Coch C; Tüting T; Schlee M; Hornung V; Hartmann G; Van den Boorn JG
Cancer Immunol Res; 2017 Jun; 5(6):455-467. PubMed ID: 28468914
[TBL] [Abstract][Full Text] [Related]
9. Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.
Nguyen DC; Shae D; Pagendarm HM; Becker KW; Wehbe M; Kilchrist KV; Pastora LE; Palmer CR; Seber P; Christov PP; Duvall CL; Wilson JT
Adv Healthc Mater; 2021 Jan; 10(2):e2001056. PubMed ID: 33225632
[TBL] [Abstract][Full Text] [Related]
10. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
11. Cutting Edge: The RIG-I Ligand 3pRNA Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination.
Hochheiser K; Klein M; Gottschalk C; Hoss F; Scheu S; Coch C; Hartmann G; Kurts C
J Immunol; 2016 Mar; 196(6):2439-43. PubMed ID: 26819202
[TBL] [Abstract][Full Text] [Related]
12. PACT- and RIG-I-Dependent Activation of Type I Interferon Production by a Defective Interfering RNA Derived from Measles Virus Vaccine.
Ho TH; Kew C; Lui PY; Chan CP; Satoh T; Akira S; Jin DY; Kok KH
J Virol; 2016 Feb; 90(3):1557-68. PubMed ID: 26608320
[TBL] [Abstract][Full Text] [Related]
13. Endothelial RIG-I activation impairs endothelial function.
Asdonk T; Motz I; Werner N; Coch C; Barchet W; Hartmann G; Nickenig G; Zimmer S
Biochem Biophys Res Commun; 2012 Mar; 420(1):66-71. PubMed ID: 22402283
[TBL] [Abstract][Full Text] [Related]
14. Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists.
Chiang C; Beljanski V; Yin K; Olagnier D; Ben Yebdri F; Steel C; Goulet ML; DeFilippis VR; Streblow DN; Haddad EK; Trautmann L; Ross T; Lin R; Hiscott J
J Virol; 2015 Aug; 89(15):8011-25. PubMed ID: 26018150
[TBL] [Abstract][Full Text] [Related]
15. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
16. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.
Glas M; Coch C; Trageser D; Dassler J; Simon M; Koch P; Mertens J; Quandel T; Gorris R; Reinartz R; Wieland A; Von Lehe M; Pusch A; Roy K; Schlee M; Neumann H; Fimmers R; Herrlinger U; Brüstle O; Hartmann G; Besch R; Scheffler B
Stem Cells; 2013 Jun; 31(6):1064-74. PubMed ID: 23390110
[TBL] [Abstract][Full Text] [Related]
17. RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Daßler-Plenker J; Reiners KS; van den Boorn JG; Hansen HP; Putschli B; Barnert S; Schuberth-Wagner C; Schubert R; Tüting T; Hallek M; Schlee M; Hartmann G; Pogge von Strandmann E; Coch C
Oncoimmunology; 2016; 5(10):e1219827. PubMed ID: 27853642
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.
Werfel TA; Jackson MA; Kavanaugh TE; Kirkbride KC; Miteva M; Giorgio TD; Duvall C
J Control Release; 2017 Jun; 255():12-26. PubMed ID: 28366646
[TBL] [Abstract][Full Text] [Related]
19. TLR ligands upregulate RIG-I expression in human plasmacytoid dendritic cells in a type I IFN-independent manner.
Szabo A; Magyarics Z; Pazmandi K; Gopcsa L; Rajnavolgyi E; Bacsi A
Immunol Cell Biol; 2014 Sep; 92(8):671-8. PubMed ID: 24839978
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides.
Murthy N; Campbell J; Fausto N; Hoffman AS; Stayton PS
J Control Release; 2003 May; 89(3):365-74. PubMed ID: 12737839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
